Cellectar Biosciences, INC DEF 14A proxy statements

Cellectar Biosciences announces its 2026 Annual Meeting of Stockholders to vote on director elections, equity plan expansion, and warrant exercise approvals.

Cellectar Biosciences, Inc. filed a supplement to its proxy statement to include an amendment for a proposed reverse stock split at a ratio between 1-for-10 and 1-for-30, to be voted on at its 2025 Annual Meeting of Stockholders.

Cellectar Biosciences is holding its annual stockholder meeting on June 13, 2025, to vote on director elections, auditor ratification, a potential reverse stock split, executive compensation, and meeting adjournment if necessary.

Cellectar Biosciences is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Cellectar Biosciences issues a supplement to its proxy statement to correct information regarding virtual meeting access for the upcoming Annual Meeting of Stockholders on June 14, 2024.

Cellectar Biosciences announces its 2024 Annual Meeting of Stockholders will be held virtually on June 14, 2024, to vote on director elections, stock incentive plan increase, auditor ratification, and executive compensation.

Cellectar Biosciences is holding its annual meeting on June 14, 2024, to vote on director elections, an increase in common stock available for issuance under the 2021 Stock Incentive Plan, ratification of the independent accounting firm, and executive compensation.